Home / News

Neuland Labs Shares Fall 5% as Q2 Profit Slumps 46.7%, Revenue Drops

• Neuland Laboratories shares fell 4.75% in early Wednesday trade after Q2 profit dropped 46.7% to ₹51.6 crore and revenue declined 12.6% year on year. • EBITDA fell 30.2% to ₹108.56 crore and margins contracted to 24.1% from 30.2% a year ago, reflecting weaker profitability during the September quarter. • Company blamed volatility on CDMO business and project execution timelines, saying commercial core segment and RFP traction remain aligned with its long-term growth plan. • The stock traded at ₹18,501, down 15.4% over one month, trimming its year-to-date advance to 22.3%.

Shares of Neuland Laboratories declined sharply in early trade on Wednesday after the pharmaceutical manufacturer reported a weak second-quarter performance that unsettled investors despite management’s insistence that the underlying growth plan remains intact. The stock fell 4.75% to ₹18,501, extending a one-month correction of 15.4% and trimming its year-to-date advance to 22.3%. The reaction followed earnings released after market hours on Tuesday, which showed a steep drop in profit and revenue for the September quarter. For the quarter ended September, Neuland reported net profit of ₹51.6 crore, down 46.7% from ₹96.9 crore a year earlier and 65% lower than ₹147.6 crore in the previous quarter. Revenue also softened, falling 12.6% year on year to ₹449.65 crore, while EBITDA declined 30.2% to ₹108.56 crore from ₹155.5 crore in the corresponding period. Margins contracted to 24.1% from 30.2% a year ago and from 34.7% in the prior quarter. Management attributed the fluctuation primarily to its contract development and manufacturing organization (CDMO) business and the timing of project execution. The company said the commercial core business segment continued to drive near-term growth, while strong request-for-proposal traction and engagement with large pharmaceutical customers supported customer diversification and a longer-term pipeline. Neuland said the results remained in line with the roadmap it has laid out, even as quarterly numbers reflected uneven execution cycles.